Status:
COMPLETED
Genetic Susceptibility to Factor VIII Inhibitors
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Hemophilia
Eligibility:
All Genders
1-100 years
Brief Summary
This international study will identify genetic factors that may influence the development of inhibitory antibodies in patients with hemophilia A after treatment with factor VIII. Bleeding episodes in ...
Detailed Description
In collaboration with investigators of the Hemophilia Inhibitor Genetic Study (HIGS) multicenter study and the University of Lund, University Hospital, Malmo, Sweden, we propose to assess the role of ...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA
- DNA and relevant clinical data from properly consented hemophiliac subjects and family members (maximum estimated = 3500) will be provided to the LGD for genotyping and analysis.
- EXCLUSION CRITERIA
- No available subjects will be excluded to maximize power.
Exclusion
Key Trial Info
Start Date :
May 24 2005
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 5 2016
Estimated Enrollment :
1187 Patients enrolled
Trial Details
Trial ID
NCT00344435
Start Date
May 24 2005
End Date
April 5 2016
Last Update
April 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital, University of Lund
Malmo, Sweden